Superworth10x Genomics EPS TXG
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$0.59
- Latest quarter, Q2 FY26
- −$0.14
- −150% on a year earlier
- Fiscal year 2025
- −$0.35
10x Genomics' earnings per share was −$0.59 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.14, down 150% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.35 | n/a |
| FY2024 | −$1.52 | n/a |
| FY2023 | −$2.17 | n/a |
| FY2022 | −$1.47 | n/a |
| FY2021 | −$0.52 | n/a |
| FY2020 | −$5.15 | n/a |
| FY2019 | −$1.35 | n/a |
| FY2018 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.14 | −150% | −$0.59 | |
| Q1 FY26 | −$0.10 | n/a | −$0.17 | |
| Q4 FY25 | −$0.13 | n/a | −$0.35 | |
| Q3 FY25 | −$0.22 | n/a | −$0.62 | |
| Q2 FY25 | $0.28 | n/a | −$0.70 | |
| Q1 FY25 | −$0.28 | n/a | −$1.30 | |
| Q4 FY24 | −$0.40 | n/a | −$1.52 | |
| Q3 FY24 | −$0.30 | n/a | −$1.53 | |
| Q2 FY24 | −$0.32 | n/a | −$2.02 | |
| Q1 FY24 | −$0.50 | n/a | −$2.23 | |
| Q4 FY23 | −$0.41 | n/a | −$2.17 | |
| Q3 FY23 | −$0.79 | n/a | −$1.91 |
Against its peers
Companies in Medical - Diagnostics & Research nearest 10x Genomics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| TXG10x Genomics | −$0.59 | |
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| LNTHLantheus | $4.13 | +10% a year |
| BLLNBillionToOne | $0.65 | |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| CDNACareDx | $2.07 | +116% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| Peer median | $3.12 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on 10x Genomics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.